ArticleNeurourology and urodynamics2025
Medium Term Outcomes for Robotic Sacral Colpopexy With Autologous Fascia Lata.
Article in Neurourology and urodynamics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Morbidity Associated with Autologous Fascia Lata Harvesting for Pelvic Floor Surgery.International urogynecology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo evaluate the medium-term outcomes of robotic sacral colpopexy (RSC) using autologous fascia lata for the treatment of apical pelvic organ prolapse.
methodsAn IRB-approved retrospective review was conducted on patients who underwent RSC with autologous fascia lata at a single institution between November 2017 and August 2022. Only patients with a minimum of 24 months of follow-up were included as short-term results have already been published. Data collected included patient demographics, operative details, surgical complications, Pelvic Organ Prolapse Quantification (POP-Q) measurements, and patient-reported outcomes using the Urogenital Distress Inventory-6 (UDI-6) and Incontinence Impact Questionnaire-7 (IIQ-7). The primary outcome was the medium-term durability of autologous fascia lata RSC, with recurrence defined as > 0 cm from the hymen in any compartment on postoperative POP-Q examination or recurrence at the apex of ≥ 2 cm.
resultsNineteen patients met the inclusion criteria, with a mean follow-up of 42.8 ± 11.9 months. All POP-Q values showed significant improvement postoperatively, with only one (6.3%) patient experiencing posterior compartment recurrence and one (6.3%) with exactly 2 cm of apical descent. One patient (5.2%) required surgical retreatment with posterior colporrhaphy and a pubovaginal sling. Patient-reported outcomes demonstrated significant improvement in UDI-6 and IIQ-7 scores (p < 0.05). Minor complications related to fascia lata harvest were observed, including seroma (10.5%), transient paresthesia (21%), hematoma (5.2%), and deep vein thrombosis (5.2%), with most resolving spontaneously.
conclusionsRSC with autologous fascia lata provides durable medium-term anatomic and symptomatic improvement for apical POP, with low recurrence and retreatment rates. While minor harvest-related complications were observed, most were self-limiting. These findings support the use of autologous fascia lata as a viable alternative to synthetic mesh in RSC. Larger, multicenter studies with extended follow-up are needed to further validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.